GlassScriptPhysician profile
Rohini Shantharam
NPI 1285077057
$4,058.57
in general payments reported to CMS, 2019-2025
27 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.06 · 2020: $154 · 2021: $338 · 2022: $498 · 2023: $852 · 2024: $1,121 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,014.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,421.97 | 2021-2025 | Rinvoq, Skyrizi, Botox |
| Allergan, INC. | $388.48 | 2021-2022 | |
| Merz North America, INC. | $244.34 | 2020-2025 | Xeomin |
| Novartis Pharmaceuticals Corporation | $230.61 | 2023-2025 | |
| Genzyme Corporation | $177.11 | 2020-2024 | |
| Janssen Biotech, INC. | $163.57 | 2021-2025 | Tremfya |
| Galderma Laboratories, L.P. | $152.87 | 2024 | Aklief |
| Revance Therapeutics, INC. | $143.65 | 2024-2025 | Daxxify |
| Incyte Corporation | $138.80 | 2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $138.61 | 2023-2025 | Blu-U |
| Organogenesis INC. | $113.64 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $85.75 | 2023-2025 | Dupixent |
| Amgen INC. | $74.24 | 2023-2024 | Otezla |
| Pfizer INC. | $71.82 | 2019-2024 | |
| Leo Pharma INC. | $70.19 | 2020-2025 | Adbry |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $58.38 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $57.31 | 2021-2025 | Cabtreo, Jublia, Siliq |
| Lilly USA, LLC | $56.39 | 2020-2023 | Olumiant, Taltz |
| E.R. Squibb & Sons, L.L.C. | $49.00 | 2023-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $45.63 | 2024-2025 | Zoryve |
| Ucb, INC. | $38.47 | 2023-2025 | Bimzelx |
| Biofrontera INC. | $34.13 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.40 | 2023 | Spevigo |
| Vyne Pharmaceuticals INC. | $20.97 | 2020 | |
| Verrica Pharmaceuticals INC. | $19.89 | 2024 | Ycanth |
| Nobelpharma America, LLC | $19.72 | 2025 | |
| Mallinckrodt Hospital Products INC. | $15.63 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohini Shantharam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.